Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2026)

Intellia Therapeutics (NTLA) has 7 years of Long-Term Investments data on file, last reported at $141.3 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $141.3 million, up 528.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $141.3 million (up 528.36% YoY), and the FY2025 annual result was $155.2 million, up 250.74% from the prior year.
• Long-Term Investments fell to $141.3 million in Q1 2026 per NTLA's latest filing, from $155.2 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $225.0 million in Q1 2023 and troughed at $7.0 million in Q3 2025.
• A 5-year average of $76.2 million and a median of $46.8 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2026: Long-Term Investments slumped 89.45% in 2022, then soared 528.36% in 2026.
• A 5-year view of Long-Term Investments shows it stood at $69.3 million in 2022, then jumped by 44.02% to $99.9 million in 2023, then plunged by 55.68% to $44.3 million in 2024, then soared by 250.74% to $155.2 million in 2025, then declined by 9.01% to $141.3 million in 2026.
• Business Quant data shows NTLA's Long-Term Investments at $141.3 million in Q1 2026, $155.2 million in Q4 2025, and $7.0 million in Q3 2025.